Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | 2.31% | 34.52 | 0.9% | $1198.16m | |
| JNJ | Johnson & Johnson | 0.46% | 141.03 | 0.7% | $1113.20m | |
| BMY | Bristol-Myers Squibb Co. | 0.29% | 59.15 | 1.0% | $977.19m | |
| MRK | Merck & Co., Inc. | 0.87% | 78.80 | 0.7% | $849.39m | |
| ABBV | AbbVie, Inc. | -0.25% | 98.89 | 1.9% | $811.21m | |
| LLY | Eli Lilly & Co. | 0.33% | 163.83 | 1.1% | $698.91m | |
| AZN | AstraZeneca Plc | 0.92% | 53.81 | 1.2% | $301.15m | |
| RPRX | Royalty Pharma Plc | -1.59% | 45.73 | 0.1% | $252.67m | |
| VXRT | Vaxart, Inc. | -7.88% | 7.37 | 0.0% | $224.54m | |
| NVS | Novartis AG | -0.32% | 87.57 | 0.2% | $160.39m | |
| GSK | GlaxoSmithKline Plc | 0.87% | 41.22 | 0.2% | $122.53m | |
| RGEN | Repligen Corp. | 1.98% | 126.65 | 7.2% | $120.14m | |
| NVO | Novo Nordisk A/S | 1.05% | 66.37 | 0.1% | $94.84m | |
| RETA | Reata Pharmaceuticals, Inc. | 2.56% | 157.85 | 3.4% | $87.71m | |
| SNY | Sanofi | 0.68% | 51.62 | 0.2% | $80.12m |
Company Profile
GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).